Guidelines

PP.01 The role of the de novo DNA methyltransferase DNMT3B in multiple myeloma cell survival and drug resistance

February 2020
PP.02 Mild Cognitive Impairment, Hypoalbuminemia, High Crp And Gi Co-Morbidities: A Frailty Score That Identifies Older Patients With Malignant Hemopathies Who Don’t Benefit From Chemotherapy

February 2020
PP.03 Shallow whole-genome sequencing of cell-free DNA for B-cell lymphoma diagnosis and disease monitoring: a standardized approach with underappreciated potential

February 2020
PP.03.2 Improvement of antibody-induced cell death in multiple myeloma

February 2020
PP.04 Loss of the tumor suppressor RASSF4 is associated with aggressive disease and poor outcome in Diffuse Large B Cell Lymphoma

February 2020
PP.05 Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

February 2020
PP.06 Capillary zone electrophoresis measured HbA2 aiding in diagnosis of underlying a-thalassemia in the presence of HbS

February 2020
PP.07 Blood products and Hematopoietic Progenitor Cells (HPC) Hepatitis E screening: current European practices and guidelines

February 2020
PP.08 Treatment of a patient with severe cytomegalovirus (CMV) infection after allogeneic haploidentical stem cell transplantation with donor CMV specific T cells

February 2020
PP.09 Hemophagocytic lymphohistiocytosis induced by visceral leishmaniasis

February 2020

Top